# A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

> **NCT01959282** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 219 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Placebo
- **DRUG:** JNJ-54781532 25 mg once daily
- **DRUG:** JNJ-54781532 75 mg once daily
- **DRUG:** JNJ-54781532 150 mg once daily
- **DRUG:** JNJ-54781532 75 mg twice daily

## Key facts

- **NCT ID:** NCT01959282
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-15
- **Primary completion:** 2015-05-20
- **Final completion:** 2015-12-05
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959282, "A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01959282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*